Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H30O3 |
| Molecular Weight | 318.4504 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@@]3(CC1=O)CC[C@H]4[C@@](C)(CCC[C@@]4(C)C(O)=O)[C@@H]3CC2
InChI
InChIKey=KFVUFODCZDRVSS-XGBBNYNSSA-N
InChI=1S/C20H30O3/c1-17-9-5-14-18(2)7-4-8-19(3,16(22)23)13(18)6-10-20(14,12-17)11-15(17)21/h13-14H,4-12H2,1-3H3,(H,22,23)/t13-,14-,17-,18+,19+,20-/m0/s1
| Molecular Formula | C20H30O3 |
| Molecular Weight | 318.4504 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19000919Curator's Comment: description was created based on several sources, including:
https://examine.com/supplements/stevia/ | https://www.ncbi.nlm.nih.gov/pubmed/15935396 | https://www.ncbi.nlm.nih.gov/pubmed/26712732
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19000919
Curator's Comment: description was created based on several sources, including:
https://examine.com/supplements/stevia/ | https://www.ncbi.nlm.nih.gov/pubmed/15935396 | https://www.ncbi.nlm.nih.gov/pubmed/26712732
Stevia is the common word to refer to the plant stevia rebaudiana which is the sweetest of the stevia species of plants and historically used as a sweetening agent. Several studies have suggested that in addition to their sweetness, steviosides and their related compounds, including rebaudioside A and isosteviol, may offer additional therapeutic benefits. These benefits include anti-hyperglycaemic, anti-hypertensive, anti-inflammatory, anti-tumor, anti-diarrheal, diuretic, and immunomodulatory actions. Isosteviol inhibits DNA polymerases and human DNA topoisomerase II. It also retards growth of three different types of human cancer cells and inhibits inflammation induced by TPA. Isosteviol had been in phase II clinical trials for the treatment of Type 2 diabetes mellitus.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1828 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15935396 |
27.5 µM [Ki] | ||
Target ID: CHEMBL5367 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15935396 |
103.0 µM [IC50] | ||
Target ID: CHEMBL4343 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15935396 |
177.0 µM [IC50] | ||
Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15935396 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.24 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18701231 |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSTEVIOL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1046.2 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18701231 |
4 mg/kg single, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSTEVIOL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
632.3 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18701231 |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSTEVIOL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
150.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18701231 |
4 mg/kg single, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSTEVIOL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
169.9 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18701231 |
4 mg/kg single, oral dose: 4 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSTEVIOL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18201205
20 mg/kg of body weight
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15935396
Isosteviol prevented the growth of human cancer cells, with LD50 values of 84-167 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:51:52 GMT 2025
by
admin
on
Mon Mar 31 18:51:52 GMT 2025
|
| Record UNII |
091QB7QO95
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
091QB7QO95
Created by
admin on Mon Mar 31 18:51:52 GMT 2025 , Edited by admin on Mon Mar 31 18:51:52 GMT 2025
|
PRIMARY | |||
|
231875
Created by
admin on Mon Mar 31 18:51:52 GMT 2025 , Edited by admin on Mon Mar 31 18:51:52 GMT 2025
|
PRIMARY | |||
|
DTXSID70950664
Created by
admin on Mon Mar 31 18:51:52 GMT 2025 , Edited by admin on Mon Mar 31 18:51:52 GMT 2025
|
PRIMARY | |||
|
C515747
Created by
admin on Mon Mar 31 18:51:52 GMT 2025 , Edited by admin on Mon Mar 31 18:51:52 GMT 2025
|
PRIMARY | |||
|
27975-19-5
Created by
admin on Mon Mar 31 18:51:52 GMT 2025 , Edited by admin on Mon Mar 31 18:51:52 GMT 2025
|
PRIMARY | |||
|
99514
Created by
admin on Mon Mar 31 18:51:52 GMT 2025 , Edited by admin on Mon Mar 31 18:51:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|